Loading...
XSHE002252
Market cap6.52bUSD
Dec 20, Last price  
7.22CNY
Name

Shanghai RAAS Blood Products Co Ltd

Chart & Performance

D1W1MN
XSHE:002252 chart
P/E
26.75
P/S
5.98
EPS
0.27
Div Yield, %
0.00%
Shrs. gr., 5y
6.12%
Rev. gr., 5y
34.58%
Revenues
7.96b
+21.27%
303,192,604278,689,993309,976,913309,860,472387,519,941483,357,124567,385,772662,676,897496,359,5581,319,735,2302,013,321,6292,326,250,3481,927,748,4251,804,235,3992,584,983,9822,761,682,0364,287,726,7496,567,198,5817,963,958,566
Net income
1.78b
-5.35%
51,242,49750,711,18081,769,205104,790,807135,663,016185,498,269200,354,617225,013,842143,794,617510,854,9401,442,414,3011,613,153,629835,828,5880607,893,7111,323,711,0551,294,510,0501,880,090,0661,779,476,930
CFO
2.28b
+32.01%
54,016,44753,584,846175,710,568107,642,052116,011,121200,209,539178,028,545263,464,6880465,961,164762,420,968638,223,427264,949,553262,500,811872,694,4701,168,847,1461,294,013,2191,725,596,0632,277,884,080
Dividend
Sep 30, 20240.037 CNY/sh

Profile

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex concentrate, human fibrinogen, human thrombin and human fibrin sealant, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. It also provides testing services for blood products, vaccines, diagnostic reagents, and testing equipment. The company also exports its products to Southeast Asia and Latin America. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.
URL
http://www.raas-corp.com
IPO date
Jun 23, 2008
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,963,959
21.27%
6,567,199
53.16%
4,287,727
55.26%
Cost of revenue
5,621,456
4,276,064
2,586,533
Unusual Expense (Income)
NOPBT
2,342,503
2,291,135
1,701,194
NOPBT Margin
29.41%
34.89%
39.68%
Operating Taxes
426,651
400,610
250,089
Tax Rate
18.21%
17.49%
14.70%
NOPAT
1,915,851
1,890,525
1,451,105
Net income
1,779,477
-5.35%
1,880,090
45.24%
1,294,510
-2.21%
Dividends
(188,742)
(168,549)
Dividend yield
0.44%
0.37%
Proceeds from repurchase of equity
(999,995)
BB yield
1.90%
Debt
Debt current
1,976
4,092
Long-term debt
2,988
3,693
8,311
Deferred revenue
9,492
12,769
15,197
Other long-term liabilities
7,059
1
Net debt
(20,372,297)
(18,905,183)
(16,018,082)
Cash flow
Cash from operating activities
2,277,884
1,725,596
1,294,013
CAPEX
(450,797)
Cash from investing activities
(670,594)
Cash from financing activities
(1,091,090)
FCF
2,053,527
1,856,754
1,272,868
Balance
Cash
4,198,311
4,215,192
2,964,969
Long term investments
16,176,975
14,695,659
13,065,516
Excess cash
19,977,087
18,582,491
15,816,099
Stockholders' equity
14,980,265
14,269,697
11,976,474
Invested Capital
14,687,592
14,432,422
13,877,792
ROIC
13.16%
13.36%
10.34%
ROCE
7.89%
7.98%
6.58%
EV
Common stock shares outstanding
6,590,655
6,740,788
6,740,788
Price
8.00
26.18%
6.34
-7.04%
6.82
-7.84%
Market cap
52,725,242
23.37%
42,736,595
-7.04%
45,972,174
-7.84%
EV
32,368,807
23,831,413
30,577,135
EBITDA
2,514,560
2,475,664
1,860,224
EV/EBITDA
12.87
9.63
16.44
Interest
458
263
472
Interest/NOPBT
0.02%
0.01%
0.03%